BNBX vs LLY · P/E 0.0, rev $2.2M vs P/E 39, rev $22.97B
Applied DNA Sciences, Inc. (BNBX) versus Eli Lilly and Company (LLY) — a side-by-side from cached financials, not a winner call.
Applied DNA Sciences, Inc. (BNBX) is a asset management company listed on NASDAQ.
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
Latest reported BNBX revenue for 2026-06-30 was $2.2M. Net income was -$29.9M. Revenue was up 38.1% from 2026-03-31 to 2026-06-30. BNBX currently screens at market cap $3.3M and trailing P/E 0.0.
Latest reported LLY revenue for 2026-06-30 was $22.97B. Net income was $7.09B. Revenue was up 16.0% from 2026-03-31 to 2026-06-30. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
BNBX currently screens at market cap $3.3M and trailing P/E 0.0. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
Not investment advice. Open the BNBX and LLY stock pages for the full models.
Not investment advice.